Webcast Next Generation Sequencing: Epi-Seq

Next Generation Sequencing: Epi-Seq

 · Australia/NSW

About This Webcast

Epigenetics is the study of heritable changes in gene expression that are not encoded in the DNA of the genome. Encouraging evidence has linked epigenetic effects to (1) oncogenesis, progression and treatment of cancer, (2) the regulation of development and function of the nervous system, (3) gene regulation, (4) cellular stress events, (5) nutrigenomics, (6) aging and DNA repair. Ongoing efforts are directed towards identifying the dynamic modifications to DNA and its associated proteins and elucidating their mechanisms. In today’s webinar we discuss two novel methods for studying epigenetic changes, EM-seq and NicE-seq, that are used to study DNA methylation and chromatin state respectively. Whole Genome Bisulfite Sequencing (WGBS) is regarded as the gold standard for methylome analysis, however, it does have its drawbacks. The chemical bisulfite reaction damages and degrades DNA, resulting in fragmentation and loss. Additionally, bisulfite libraries demonstrate significant GC bias and are enriched for methylated regions. To overcome these limitations, we developed a method for identification of 5mC and 5hmC called NEBNext Enzymatic Methyl-seq (EM-seq). This method is exclusively enzyme based, resulting in less DNA damage and therefore more even genome coverage and reliable methylation calls. Chromatin accessibility is the measure of how "accessible" or "open" a region of the genome is to binding of transcription factors and other DNA binding proteins to regulate gene expression. Changes in chromatin accessibility are important epigenetic regulatory processes that govern cell or context-specific expression of genes. DNase hypersensitive assay, FAIRE-seq, NOMe-seq, and ATAC-seq are some of the methods used for interrogating chromatin accessibility. Nicking enzyme assisted sequencing (NicE-seq) is a novel method that captures and reveals open chromatin sites (OCSs) and transcription factor occupancy at single nucleotide resolution, coincident with DNase hypersensitive and ATAC-seq sites at a lower sequencing burden. In this webinar, Dr. Chaithanya Ponnaluri will provide an overview of EPI-Seq and discuss these two novel methods developed at NEB. The topics covered will include: Introduction to Epigenomics Enzymatic Methyl-seq – DNA Methylation NicE-seq – Open Chromatin Profiling NEB Tools and Resources

Speakers

Chaithanya Ponnaluri, PhD.

Chaithanya Ponnaluri, PhD.

Development Scientist , New England Biolabs

Chaithanya Ponnaluri, PhD,is a Development Scientist in the NEBNext Group at New England Biolabs, Boston. He received his PhD from University of Missouri – Kansas City, where he studied KDM4 family of histone demethylases and screened for inhibitors of HIF pathway which are critical for cellular hypoxic response. Chaithanya joined NEB in July 2014 as a post-doctoral fellow in Dr. Sriharsa Pradhan’s lab. His work was focused on identifying novel interacting partners of DNMT1 to elucidate their role in the maintenance of DNA methylation. He also worked on developing tools like NicE-seq to evaluate chromatin dynamics. In 2017, he joined the NEBNext team as a development scientist and worked on the development and launch of Enzymatic Methyl-seq.

Selva Ramasubramanian, PhD

Selva Ramasubramanian, PhD

Field Application Scientist , New England Biolabs

Selva Ramasubramanian, PhD,is a Field Application Scientist at New England Biolabs, ANZ. Selva received her PhD from the Max Planck Institute (MPIPZ, Germany) and moved to Australia as a visiting scientist at Monash University (Department of Biological Science, Melbourne). Selva also has Biopharmaceutical experience (Biocon Biopharmaceuticals) in Bioanalytical Division - Monoclonal Antibody Characterization. Selva joined the Monash Health Translation Precinct (MHTP) - Core Medical Genomics Facility as Single Cell Genomics Manager. In the Genomics space, she possesses broad knowledge including Project Design consultations, significant hands-on experience with different Genomic platforms and technical capabilities.